financetom
Business
financetom
/
Business
/
Goldman, BASF, others in $20 million platinum, palladium price-fixing settlement
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Goldman, BASF, others in $20 million platinum, palladium price-fixing settlement
Aug 29, 2024 8:52 AM

NEW YORK (Reuters) -Goldman Sachs ( GS ), German industrial company BASF and two other banks agreed to pay $20 million to settle a nearly decade-old antitrust lawsuit accusing them of conspiring to suppress platinum and palladium prices.

A preliminary settlement of the proposed class action was filed on Friday night and approved by U.S. District Judge Gregory Woods in Manhattan, court records on Monday show.

The defendants also include HSBC ( HSBC ) and London-based ICBC Standard Bank. All four defendants denied wrongdoing in agreeing to settle.

Platinum and palladium are used in catalytic converters to curb vehicle emissions, and also in dentistry and jewelry.

Purchasers of platinum, palladium and futures contracts for the metals accused the defendants of conspiring from Jan. 1, 2008 to Nov. 30, 2014 to rig the twice-daily platinum and palladium "fixings" by sharing customer data, front-running expected price moves, and placing bogus "spoof" orders.

The purchasers said lower metals prices reduced the cost that banks and their clients paid for platinum and palladium, and enabled banks to avoid losses on "short" positions they maintained in futures markets.

Lawyers for the purchasers called the settlement an "excellent" result that was fair, reasonable and adequate.

They plan to seek up to one-third of the settlement, or $6.67 million, in legal fees, plus up to $600,000 for expenses.

Final settlement approval is possible in January.

The lawsuit is one of several in the Manhattan court accusing big banks of colluding in various markets including interest rate benchmarks, U.S. Treasuries, currencies and commodities.

The case is In re: Platinum and Palladium Antitrust Litigation, U.S. District Court, Southern District of New York, No. 14-09391.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Saudi says OPEC+ can pause or reverse oil output boost, criticises Goldman Sachs
Saudi says OPEC+ can pause or reverse oil output boost, criticises Goldman Sachs
Jun 6, 2024
* Saudi energy minister says Goldman created bearish narrative * Russia says OPEC+ ready to adjust the deal * OPEC SecGen says oil demand is good (Releads with Saudi minister comments) By Vladimir Soldatkin and Olesya Astakhova ST PETERSBURG, June 6 (Reuters) - OPEC+ can pause or reverse oil production increases if the market weakens, the Saudi energy minister said...
Dolby Laboratories To Acquire GE Licensing In $429M Cash Deal: Strengthens Patent Portfolio
Dolby Laboratories To Acquire GE Licensing In $429M Cash Deal: Strengthens Patent Portfolio
Jun 6, 2024
Dolby Laboratories, Inc. ( DLB ) , known for its entertainment services, announced a definitive agreement to acquire GE Aerospace’s GE Licensing, which specializes in intellectual property licensing in the consumer digital media and electronics sectors. Dolby Laboratories ( DLB ) will acquire GE Licensing in a $429 million all-cash transaction, expected to close by the end of fiscal year...
Borealis Foods' Board Approves $3 Million Share Buyback Plan
Borealis Foods' Board Approves $3 Million Share Buyback Plan
Jun 6, 2024
12:11 PM EDT, 06/06/2024 (MT Newswires) -- Borealis Foods ( BRLS ) said Thursday that its board has authorized a $3 million stock buyback program, with an expiration date of May 30, 2025. The program is expected to be funded using cash on hand and from operations, the company said. Shares of Borealis Foods ( BRLS ) were 1.3% lower...
Vanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal
Vanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal
Jun 6, 2024
Vanda Pharmaceuticals Inc ( VNDA ). received an acquisition offer from Cycle Pharmaceuticals Ltd worth $8 per share, representing a total cash consideration of $466 million. Cycle Pharmaceuticals, founded in 2012, focuses on rare metabolic, immunological, and neurological genetic conditions. Within neurological conditions, Cycle focuses on multiple sclerosis. In May, Cycle launched its sixth drug product in the U.S. market....
Copyright 2023-2026 - www.financetom.com All Rights Reserved